News Release For Immediate Release Media Contact: Kari McHugh Kari.McHugh@breakthroughcancer.org   Collaboration with Revolution Medicines to Study Biomarkers for RAS(ON) Multi-Selective Inhibitor in Pancreatic Cancer The expanded phase 1 clinical trial is using serial biopsies and blood samples to analyze the tumor response to RMC-6236 at an unprecedented level of detail.   (CAMBRIDGE, MASS.) December 19, 2024 – Break Through Cancer has launched a collaborative cohort for a Phase 1 study of RMC-6236, a compound developed by Revolution Medicines that is designed to suppress multiple RAS proteins that drive human cancers, including pancreatic cancer, non-small cell lung cancer and colorectal......

Continue reading

News Release For Immediate Release Media Contact: Kari McHugh Kari.McHugh@breakthroughcancer.org   Break Through Cancer Launches Team to Prevent Lung Cancer Recurrence with the Hope of Long-term Cures. Top cancer researchers unite in radical collaboration to target residual lung cancer cells remaining after initial therapy. (CAMBRIDGE, MASS.) December 05, 2024 – Lung cancer is the leading cause of cancer death worldwide, with various subtypes affecting millions of people each year. Among these, ALK-positive lung cancer frequently strikes younger people who have never smoked, including those aged between 20 and 50. Upon diagnosis, 80% of individuals already have stage 4 metastatic cancer,......

Continue reading

News Release For Immediate Release Media Contact: Kari McHugh Kari.McHugh@breakthroughcancer.org   Break Through Cancer Announces First Patient Enrolled in Phase 2 Trial  Targeting Residual Disease in AML The novel study explores the effects of menin inhibition in acute myeloid leukemia with minimal residual disease as an endpoint. (CAMBRIDGE, MASS.) November 1, 2024 – Break Through Cancer, a Boston-based cancer research foundation, has launched a clinical trial to explore if an investigational drug can eliminate minimal residual disease (MRD) in acute myeloid leukemia (AML). AML often responds well to initial treatment, but residual cancer cells frequently cause relapse. Break Through Cancer’s......

Continue reading

News Release For Immediate Release Media Contact: Kari McHugh Kari.McHugh@breakthroughcancer.org   No More “Wait and See”: Two Clinical Trials Target the Origins of Recurrent Ovarian Cancer Break Through Cancer scientists are evaluating a “second-look” technique to measure and destroy persistent cancer cells resistant to frontline chemotherapy. (CAMBRIDGE, MASS.) September 26, 2024 – After initial therapy to treat ovarian cancer, a small number of cancer cells, undetectable on scans, often linger in the body. These cells, referred to as minimal residual disease (MRD), are the seed from which cancer can and does recur for most women diagnosed with stage III or......

Continue reading

News Release For Immediate Release Media Contact: Kari McHugh Kari.McHugh@breakthroughcancer.org   Break Through Cancer and ALK Positive, Inc. Team Up to Conquer ALK-Positive Lung Cancer with a $2 Million, Multi-year, Research Partnership   CAMBRIDGE, MA, May 9, 2024 /Break Through Cancer announces a new partnership with ALK Positive Inc. (ALK Positive), a foundation funded by patients with ALK-positive lung cancer and their families. ALK Positive and Break Through Cancer are joining forces to fund a new initiative in lung cancer research with the hope of creating durable responses and cures for patients with ALK-positive lung cancer. ALK Positive is the......

Continue reading